Trial Profile
OPuS-4: An open-label study to evaluate the long-term safety of avoralstat in subjects with hereditary angioedema
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Avoralstat (Primary)
- Indications Angioedema
- Focus Adverse reactions
- Acronyms OPuS 4
- Sponsors BioCryst Pharmaceuticals
- 16 Feb 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 02 Dec 2015 New trial record